NAMS ▲ +0.7% - NewAmsterdam Pharma Company N.V. $NAMS NAMSW - NewAmsterdam Pharma and Menarini Group Receive European Commission Approval for Ubeslo® (Obicetrapib Monotherapy) and Evlarco® (Obicetrapib Plus Ezetimibe Fixed-Dose Combination) NewAmsterdam Pharma gained 0.7% after announcing European Commission approval for its two obicetrapib-based cholesterol medications, Ubeslo® and Evlarco®, in partnership with Menarini Group. The regulatory clearance opens the European market for these treatments, which target patients with elevated cholesterol levels. 21-SEP-2026 09:01 AM ET